Epidemiology, clinical picture and physical exam of plantar ulcers
Keywords:
ÚLCERAS PLANTARES/epidemiologÃa fisiopatologÃaAbstract
Objectives: A bibliographical review of the frequency was done clinical picture and physical exam to be done in plantar ulcers.
Development: A review was done in which is underline ulcer prevalence plantar perforated ulcer in different parts of the world, showing that 15% all diabetics suffer it, as well as clinical manifestations that are present in these patients. It is enphasize how to do the physical exam in these patients to determine the ulcer's area or the plantar places with possibilities for its appearance. Conclusions: A review of the frequency of planter ulcer is done, clinical picture as well as physical exam to be done.Downloads
Download data is not yet available.
References
1)Bennett PJ, Stocks AE, Whittam DJ. Analysis of risk factors for neuropathic foot ulceration in diabetes mellitus. J Am Podiatr Med Assoc 1996; 86(3):112-6.
2) Mark P, Slovenkai MD. Prevention and treatment of diabetes and its complications. Foot problems in diabetes. Med Clin NA 1998; 82(4):949.
3)Kaufman MW, Bowsher JE. Preventing diabetic foot ulcers. Med Surg Nurs 1994; 3(3):204-10.
4) Albert S. Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg 2002; 19(4):483-91.
5) Colombia. Servicio de Salud. Ultimas Normas. Guía de atención a diabetes tipo II .Parte de resolución número 00412 del 2000. Bogotá: Servicio de Salud; 2000.
6) Guzmán Cayado M. El pie diabético. Rev Cubana Invest Biomed 1999; 18(3):231-5.
7) Alleyne SG. La diabetes: una declaración para las Américas. Paname Health Org 1996; 30(3):261-65.
8) Jude E, Armstrong DG. Assessment of the diabetic foot. In: Chronic Wound Care. 3 ed. New York:McGraw Hill; 2001. pp. 589-596.
9)Green MF, Aliabadi Z, Bryant DA, Green MD. Diabetic foot: evaluation and management. South Med J 2002; 95(1):95-101.
10) Sanders LJ. Diabetes mellitus. Prevention of amputation. J Am Podiatr Med Assoc 1994; 64(7):322-8.
11) Gulam-Abbas Z, Lutale JK, Murbach S, Archibald LK. Clinical outcome of diabetes patients hospitalized with foot ulcers. Dares Salaam, Tanzania. Diabet Med 2002; 19(7):575-9.
12)Knighton DR , Fiegel UD. Growth factors and comprehensive surgical care of diabetic wounds. Curr Opin Gen Surg1993; (2):32-9.
13) Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputation in diabetes. In: Diabetes in America, 2 ed. London:Mosby; 2000. pp 409.
14)Dinht J, Pham H, Veves A. Emerging treatments in diabetic wounds. Clin Podiatr Med Surg 2000; 14(1):2-10.
15)Rudolph J, Mannari Pa-c, Wyatt G, Payne MD, Diane E, Ochs R. Successful treatment of recalcitrant diabetic heel ulcers with topical Becaplermin (Rh PDGF-BB) gel wounds 2002; 14(3):116-21.
16) Levin EM. Chronic complications of diabetes foot lesions in patients with diabetes mellitus. Endocrinology and Metabolism Clinics. New York: W B Saunders 1996; 25(2):445-62.
17)Muller IS, De Grauw WJ, Van Gerwen WH, Bartelink ML, Van Der Hoogen HJ, Rutlen GE. Foot ulceration and lower limb amputation in type 2 diabetic patients in dutch primary health care. Diabetes Care 2002; 25(3):570-4.
18) Kumar S, Ashe HA, Parnell LN, Fernandez DJ, Tsigos C, Young RJ. The prevalence of foot ulceration and it’s come lates in type 2 diabetic patients: a population based study. Diabetic Med 1994; 11(5):480-4.
19) Apelquist S, Larsson J, Agardh CD. Long-term prognosis for diabetic patients with foot ulcers. J Intern Med 1993; 233(6):485-91.
20)O´rourque, Heard S, Treacy J, Graven R, Whitbread C. Risk to feet in the top end; outcome of diabetic foot complications. Am J Surg 2002; 72(4):282-6.
21)Apelqvist J, Ragnarson-Tennvall G, Larsson J, Persson V. Long- term cost for foot ulcers in diabetic patients in a multidisciplinary setting. Foot Ankle Int 1995; 16(7):388-94.
22) Halimi S, Benhamou PY, Charras H. Cost of the diabetic foot. Diabet Metab 1993; 19(5 suppl):518-22.
23)Apelquist J, Ragnarson-Tennvall G, Persson V, Larsson J. Diabetic foot ulcers in a multidisciplinary setting an economic analysis of primary healing an healing with amputation. J Intern Med; 235(5):463-71.
24)Migdalis IN, Xenos K, Chairopoulos K. Ca(2+)-Mg(2+)-Atpase activity and ionized calcium in type 2 diabetic patients with neuropathy. Diabetes Res Clin Pract 200; 49(2-3):113-18.
25) Martínez Conde FA, Paredes Fernández CM, Sacarías Castillo R. Neuropatía diabética. Rev Hosp Gral Dr. M Gea González 2002; 5(1-2):7-23.
26) Romero Mestre JC, Licea Puig M. Patogénesis de la polineuropatía diabética. Rev Cubana Endocrinol 1996;(7):1-7.
27)Bickel A, Botz M, Schmelz M, Handnerker HO, Neundurfer B. Density of sympathetic axons insural nerve biopsies of neuropathy patients is related to painfulness. Pain 2000; 84(2-3):413-19.
28)Dickinson PJ, Carrington AL, Frost GS, Boulton AJ. Neurovascular disease antioxidants and glycation in diabetes. Diabetes Metab Res Rev 2002;18(4):260-72.
29)Olmos PR, Cataland S, O´Dorisio T M, Casey C A, Smead W L, Simon SR. The Semmes Weinstein monofilament as a potential predictor of foot ulceration in patients with noninsulin-dependent diabetes. Am J Med Sci 1995; 309(2):76-82.
30) Mueller M J. Identifying patients with diabetes mellitus who are at risk for lower extremity complications: Use of Semmes Weinstein monofilaments. Phys Ther 1996; 76(1): 68-71.
31) Young M J, Breddy J L, Veves A, Boulton A J. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 1994; 17(6): 557-60.
32)Gin H, Rigalleau V, Baillet L, Rabemanantsoa C. Comparison between monofilament, tuning fork and vibration perception test for screening patients at risk of foot complication. Diabetes Metab 2002; 28(6pt 1):457-61.
33)McNeely MJ, Boyko EJ, Ahroni JH, Stensel VL, Reiber GE, Smith DG, Pecorano RF. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care 1995; 18(2): 216-9.
2) Mark P, Slovenkai MD. Prevention and treatment of diabetes and its complications. Foot problems in diabetes. Med Clin NA 1998; 82(4):949.
3)Kaufman MW, Bowsher JE. Preventing diabetic foot ulcers. Med Surg Nurs 1994; 3(3):204-10.
4) Albert S. Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg 2002; 19(4):483-91.
5) Colombia. Servicio de Salud. Ultimas Normas. Guía de atención a diabetes tipo II .Parte de resolución número 00412 del 2000. Bogotá: Servicio de Salud; 2000.
6) Guzmán Cayado M. El pie diabético. Rev Cubana Invest Biomed 1999; 18(3):231-5.
7) Alleyne SG. La diabetes: una declaración para las Américas. Paname Health Org 1996; 30(3):261-65.
8) Jude E, Armstrong DG. Assessment of the diabetic foot. In: Chronic Wound Care. 3 ed. New York:McGraw Hill; 2001. pp. 589-596.
9)Green MF, Aliabadi Z, Bryant DA, Green MD. Diabetic foot: evaluation and management. South Med J 2002; 95(1):95-101.
10) Sanders LJ. Diabetes mellitus. Prevention of amputation. J Am Podiatr Med Assoc 1994; 64(7):322-8.
11) Gulam-Abbas Z, Lutale JK, Murbach S, Archibald LK. Clinical outcome of diabetes patients hospitalized with foot ulcers. Dares Salaam, Tanzania. Diabet Med 2002; 19(7):575-9.
12)Knighton DR , Fiegel UD. Growth factors and comprehensive surgical care of diabetic wounds. Curr Opin Gen Surg1993; (2):32-9.
13) Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputation in diabetes. In: Diabetes in America, 2 ed. London:Mosby; 2000. pp 409.
14)Dinht J, Pham H, Veves A. Emerging treatments in diabetic wounds. Clin Podiatr Med Surg 2000; 14(1):2-10.
15)Rudolph J, Mannari Pa-c, Wyatt G, Payne MD, Diane E, Ochs R. Successful treatment of recalcitrant diabetic heel ulcers with topical Becaplermin (Rh PDGF-BB) gel wounds 2002; 14(3):116-21.
16) Levin EM. Chronic complications of diabetes foot lesions in patients with diabetes mellitus. Endocrinology and Metabolism Clinics. New York: W B Saunders 1996; 25(2):445-62.
17)Muller IS, De Grauw WJ, Van Gerwen WH, Bartelink ML, Van Der Hoogen HJ, Rutlen GE. Foot ulceration and lower limb amputation in type 2 diabetic patients in dutch primary health care. Diabetes Care 2002; 25(3):570-4.
18) Kumar S, Ashe HA, Parnell LN, Fernandez DJ, Tsigos C, Young RJ. The prevalence of foot ulceration and it’s come lates in type 2 diabetic patients: a population based study. Diabetic Med 1994; 11(5):480-4.
19) Apelquist S, Larsson J, Agardh CD. Long-term prognosis for diabetic patients with foot ulcers. J Intern Med 1993; 233(6):485-91.
20)O´rourque, Heard S, Treacy J, Graven R, Whitbread C. Risk to feet in the top end; outcome of diabetic foot complications. Am J Surg 2002; 72(4):282-6.
21)Apelqvist J, Ragnarson-Tennvall G, Larsson J, Persson V. Long- term cost for foot ulcers in diabetic patients in a multidisciplinary setting. Foot Ankle Int 1995; 16(7):388-94.
22) Halimi S, Benhamou PY, Charras H. Cost of the diabetic foot. Diabet Metab 1993; 19(5 suppl):518-22.
23)Apelquist J, Ragnarson-Tennvall G, Persson V, Larsson J. Diabetic foot ulcers in a multidisciplinary setting an economic analysis of primary healing an healing with amputation. J Intern Med; 235(5):463-71.
24)Migdalis IN, Xenos K, Chairopoulos K. Ca(2+)-Mg(2+)-Atpase activity and ionized calcium in type 2 diabetic patients with neuropathy. Diabetes Res Clin Pract 200; 49(2-3):113-18.
25) Martínez Conde FA, Paredes Fernández CM, Sacarías Castillo R. Neuropatía diabética. Rev Hosp Gral Dr. M Gea González 2002; 5(1-2):7-23.
26) Romero Mestre JC, Licea Puig M. Patogénesis de la polineuropatía diabética. Rev Cubana Endocrinol 1996;(7):1-7.
27)Bickel A, Botz M, Schmelz M, Handnerker HO, Neundurfer B. Density of sympathetic axons insural nerve biopsies of neuropathy patients is related to painfulness. Pain 2000; 84(2-3):413-19.
28)Dickinson PJ, Carrington AL, Frost GS, Boulton AJ. Neurovascular disease antioxidants and glycation in diabetes. Diabetes Metab Res Rev 2002;18(4):260-72.
29)Olmos PR, Cataland S, O´Dorisio T M, Casey C A, Smead W L, Simon SR. The Semmes Weinstein monofilament as a potential predictor of foot ulceration in patients with noninsulin-dependent diabetes. Am J Med Sci 1995; 309(2):76-82.
30) Mueller M J. Identifying patients with diabetes mellitus who are at risk for lower extremity complications: Use of Semmes Weinstein monofilaments. Phys Ther 1996; 76(1): 68-71.
31) Young M J, Breddy J L, Veves A, Boulton A J. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 1994; 17(6): 557-60.
32)Gin H, Rigalleau V, Baillet L, Rabemanantsoa C. Comparison between monofilament, tuning fork and vibration perception test for screening patients at risk of foot complication. Diabetes Metab 2002; 28(6pt 1):457-61.
33)McNeely MJ, Boyko EJ, Ahroni JH, Stensel VL, Reiber GE, Smith DG, Pecorano RF. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care 1995; 18(2): 216-9.
Downloads
How to Cite
1.
Hernández Cañete CM, Sánchez Montiel ME. Epidemiology, clinical picture and physical exam of plantar ulcers. Mediciego [Internet]. 2004 Dec. 4 [cited 2024 Nov. 23];10(2). Available from: https://revmediciego.sld.cu/index.php/mediciego/article/view/2701
Issue
Section
Review article
License
Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
